[en] The non-competitive NMDA antagonist ketamine is an old drug that traditionally has been used as an anesthetic with unique properties dissociative anesthesia. More recently, it has been repeatedly shown that a single dose of ketamine is able to quickly relieve major depressive symptoms (including suicidal thoughts) in severely affected patients. This effect appears to be transient (the effect lasts less than one week), robust and reproducible, although several questions on its clinical use remain to be addressed.
We therefore propose to test the hypothesis that ketamine and/or its metabolites acutely enhance serotoninergic (5HT) transmission by either modulating afferent synaptic transmission onto serotonin neurons of the dorsal raphe or changing their intrinsic excitability. We set out to directly test this hypothesis using whole-cell patch clamp recordings in brainstem slices from juvenile (P21-P30) rats. We used a conventional bicarbonate-based Ringer and a KCl-based intrapipette solution. This allowed us to discriminate presumed 5HT from non-5HT neurons. 5HT neurons were identified as cells generating an outward current > 30 pA in voltage clamp at -60 mV during superfusion of 100 nM of the 5HT1A agonist 8-OH-DPAT (calculated EK was = -93 mV).
We first tested Ketamine’s effect on sEPSCs by using 10µM gabazine and 1 µM CGP55845. We found that 10 µM racemic ketamine increase the AMPA EPSCs in terms of amplitude and frequency in the half of 5HT recorded neurons (N total = 18).This effect was not observed in the case of non-5HT recorded neurons (N = 6). The same effect was observed by the racemate of its metabolite 2,6 hydroxynorketamine (HNK). In current clamp recordings, both ketamine and HNK increased the firing of 5HT neurons in whole-cell recordings when AMPA, NMDA, GABAA and GABAB receptors were blocked.
In conclusion, ketamine and its metabolite HNK robustly enhance AMPA EPSCs onto a subgroup of pharmacologically identified 5HT neurons. It remains to be determined whether this subgroup projects to specific targets, given that subpopulations of DR 5HT neurons have been shown to have specific and non-overlapping projections (Ren et al., Cell 175, 472-487, 2018).
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Hmaied, Cyrine ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Pharmacologie
Koulchitsky, Stanislav
Seutin, Vincent ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Pharmacologie
Language :
English
Title :
EFFECT OF KETAMINE ON THE EXCITABILITY OF DORSAL RAPHE NEURONS
Publication date :
10 May 2019
Event name :
BELGIAN SOCIETY OF PHYSIOLOGY AND PHARMACOLOGY
Event place :
Brussels, Belgium
Event date :
10-10-2019
Funders :
F.R.S.-FNRS - Fonds de la Recherche Scientifique WBI - Wallonie-Bruxelles International
Funding text :
Bourse d’excellence from Wallonie Bruxelles International (WBI)
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.